The subject invention provides a modified release solid oral dosage form comprising a therapeutically effective amount of Pridopidine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable rate controlling excipient, wherein the solid oral dosage form provides an in vivo plasma pridopidine concentration profile having a Mean Cmax of about 1,400 ng/ml or less. The subject invention also provides a method of treating an individual afflicted with a neurodegenerative disease or disease related to dopamine, comprising once daily administration of a modified release solid oral dosage form.本發明提供一種包含治療有效量之普多比啶(Pridopidine)或其醫藥上可接受的鹽及至少一種醫藥上可接受的速率控制賦形劑之修飾釋放固體口服劑型，其中該固體口服劑型提供平均Cmax為約1,400ng/ml或更小之活體內血漿普多比啶濃度曲線(profile)。本發明亦提供一種治療罹患神經退化性疾病或與多巴胺有關之疾病之個體的方法，其包括每日一次地投與修飾釋放固體口服劑型。
